An interventional study of Spinal Anesthesia and Intrathecal Bupivacaine in Pre-Eclampsia and Cesarean Section, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to female participants aged 19 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-09-05.
Sponsored by Mansoura University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Pre-Eclampsia with a site in Egypt — 11 open to participants now, 12 under way, none of them phase 3. Pre-Eclampsia · Egypt.
Among the 79 studies in Pre-Eclampsia with a site in Egypt, this one is the 13th largest by enrollment of the 40 interventional ones that give a count, is one of 11 that started in 2017, is one of 21 with no phase, and was the 19th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 244 are open to participants now.
Browse Pre-Eclampsia studies →11 of the 79 studies in Pre-Eclampsia with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 20–40 · Women only
Tanta University · Sites in Egypt
Ages 18–40 · Women only · Healthy volunteers
South Valley University · Sites in Egypt
Ages 18–50 · Women only · Healthy volunteers
Ain Shams Maternity Hospital · Sites in Egypt
Ages 18+ · Women only
Ain Shams University · Sites in Egypt
Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 161 Pre-Eclampsia studies recruiting now, 80 (50%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.
This study: 19 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 9
First in 2013; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 100 across the 40 interventional studies, 90 across the 39 observational. Of the 39 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 79 have an industry lead sponsor. The 10 most frequent:
Mansoura University is the lead sponsor of 1,121 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Mansoura University has 3 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
2 of the studies in Pre-Eclampsia with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423741South Valley UniversityUltrasonographical Assessment of Airway Indices in Pregnancy | 2026-11 |
| NCT07443345Cairo UniversityIncidence of Postoperative Diaphragmatic Dysfunction in Pregnant Women With Preeclampsia | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies in Pre-Eclampsia with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare between combination of colloids/crystalloids and crystalloids in women with preeclampsia undergoing elective cesarean delivery under spinal anesthesia
This randomized, controlled, double blind study will be conducted on women with preeclampsia with singleton pregnancy undergoing elective cesarean delivery under spinal anesthesia. Immediately, after spinal anesthesia administration, patients will receive either 250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes (Combination group) or 250 mL crystalloid over 5 minutes followed by 500 mL over 55 minutes then 250 mL over 60 minutes (Crystalloid group). The studied maternal outcomes will be the urine output, ephedrine requirement, incidence of hypotension, inferior vena cava diameters, nausea/vomiting and bradycardia. Neonatal Apgar scores will be recorded at 1 and 5 minutes post-delivery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
Procedure: Spinal Anesthesia · Drug: Intrathecal Bupivacaine · Drug: Intrathecal Fentanyl · Procedure: Cesarean Delivery · Radiation: Ultrasound Assessment of the Inferior Vena Cava · Drug: 250 mL Colloid over 5 minutes · Drug: 500 mL Crystalloid over 55 minutes · Drug: 250 mL Colloid over 60 minutes · Drug: Intravenous Ephedrine · Drug: Intravenous Syntocinon
250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
Procedure: Spinal Anesthesia · Drug: Intrathecal Bupivacaine · Drug: Intrathecal Fentanyl · Procedure: Cesarean Delivery · Radiation: Ultrasound Assessment of the Inferior Vena Cava · Drug: 250 mL Crystalloid over 5 minutes · Drug: 500 mL Crystalloid over 55 minutes · Drug: 250 mL Crystalloid over 60 minutes · Drug: Intravenous Ephedrine · Drug: Intravenous Syntocinon
Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Fentanyl 15 μg will be administered in the subarachnoid space
Lower segment cesarean section using the Pfannenstiel incision
The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
Total urine output at 2 hours post-spinal
Time frame: 2 hours after intrathecal injection
Urine output at 1 hour post-spinal
Time frame: 1 hour after intrathecal injection
Incidence of oliguria
Total urine output at 2 hours post-spinal \<60 mL
Time frame: 2 hours after intrathecal injection
Total ephedrine dose
Time frame: Intraoperative
Pre-delivery ephedrine dose
Time frame: From intrathecal injection until delivery
Number of patients requiring ephedrine
Time frame: Intraoperative
Number of patients requiring ephedrine pre-delivery
Time frame: From intrathecal injection until delivery
Incidence of nausea and/or vomiting
Time frame: Intraoperative
Incidence of bradycardia
Heart rate \<50 beats/minute
Time frame: Intraoperative
Maximum and minimum inferior vena cava diameters
Time frame: Baseline, at 5 minutes post-spinal, immediately after delivery of the fetus, and at 1 and 2 hours post-spinal
Inferior vena cava collapsibility index
Time frame: Baseline, at 5 minutes post-spinal, immediately after delivery of the fetus, and at 1 and 2 hours post-spinal
Neonatal Apgar score
Time frame: At 1 and 5 minutes after delivery
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Jul 2021, 46 months.
Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 46 months is above that.
Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.